rosacea

The suit is the second filed by the plaintiffs this year against a generic drug manufacturer for allegedly infringing patents protecting Galderma's rosacea treatment Oracea by filing an ANDA for a generic version of the drug.

Although SUNY and NYU's financial stake in the proceedings is unclear, they are seeking to protect a royalty stream that dates back to a 1992 licensing agreement with Galderma predecessor Collagenix Pharmaceuticals for some of the patents protecting Oracea, which exceeded $50 million in sales in 2007.